ArticleDiscover mental health2026
Investigating NF-κB as a biomarker for suicidal ideation in depression in a pilot case-control study.
Article in Discover mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuicidal ideation (SI) is an emotional symptom of major depressive disorder (MDD) that significantly impacts the quality of life of affected individuals. The relationship between inflammation and suicide is both complex and bidirectional. Neuroinflammation has been increasingly implicated in the pathophysiology of depression and SI. Toll-like receptors (TLRs) trigger Nuclear Factor Kappa B (NF-κB) activation, initiating immune responses and inflammation when they recognize pathogens or danger signals.
objectiveThis study aimed to investigate the relationship between NF-κB expression levels and symptoms, SI in depressive patients.
methodsThis case-control study included 60 patients diagnosed with MDD. Based on clinical assessment, Beck Depression Inventory-II (BDI-II), and Hamilton Depression Rating Scale (HDRS) scores, participants were stratified into three subgroups: 20 individuals with recent SI within the past month, 20 with a past history of SI but no such thoughts in the last month, and 20 with no history of SI, serving as the control group. Blood levels of NF-κB were measured using a Human NF-κB enzyme-linked immunosorbent assay (ELISA)Kit.
resultsA weak, inverse association was observed between patients with a history of SI and NF-κB levels compared to patients without a history of SI.
conclusionsThe findings of the present study suggest that depressed patients with SI may have impaired expression of NF-κB. A decrease in blood levels of NF-κB, among other influencing factors, could serve as a potential predictor of SI in patients with MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.